- Home
- CHPT vs RCKT Comparison
CHPT vs RCKT Comparison
Compare CHPT & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- RCKT
- Stock Information
- Founded
- CHPT 2007
- RCKT 1999
- Country
- CHPT United States
- RCKT United States
- Employees
- CHPT N/A
- RCKT N/A
- Industry
- CHPT Industrial Specialties
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- CHPT Consumer Discretionary
- RCKT Health Care
- Exchange
- CHPT Nasdaq
- RCKT Nasdaq
- Market Cap
- CHPT 340.1M
- RCKT 328.6M
- IPO Year
- CHPT N/A
- RCKT N/A
- Fundamental
- Price
- CHPT $11.29
- RCKT $3.28
- Analyst Decision
- CHPT Hold
- RCKT Buy
- Analyst Count
- CHPT 10
- RCKT 13
- Target Price
- CHPT $29.13
- RCKT $12.96
- AVG Volume (30 Days)
- CHPT 532.9K
- RCKT 6.0M
- Earning Date
- CHPT 09-03-2025
- RCKT 08-07-2025
- Dividend Yield
- CHPT N/A
- RCKT N/A
- EPS Growth
- CHPT N/A
- RCKT N/A
- EPS
- CHPT N/A
- RCKT N/A
- Revenue
- CHPT $407,681,000.00
- RCKT N/A
- Revenue This Year
- CHPT $2.79
- RCKT N/A
- Revenue Next Year
- CHPT $24.20
- RCKT $108.43
- P/E Ratio
- CHPT N/A
- RCKT N/A
- Revenue Growth
- CHPT N/A
- RCKT N/A
- 52 Week Low
- CHPT $8.55
- RCKT $2.19
- 52 Week High
- CHPT $39.20
- RCKT $22.01
- Technical
- Relative Strength Index (RSI)
- CHPT 47.09
- RCKT 51.17
- Support Level
- CHPT $11.41
- RCKT $2.88
- Resistance Level
- CHPT $11.85
- RCKT $3.74
- Average True Range (ATR)
- CHPT 0.59
- RCKT 0.27
- MACD
- CHPT 0.08
- RCKT 0.02
- Stochastic Oscillator
- CHPT 39.55
- RCKT 35.43
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.